New hope for High-Risk sarcoma: targeted drug combo tested in kids and young adults

This study tests a new treatment approach for patients with Ewing sarcoma or desmoplastic small round cell tumors, especially those at high risk of the cancer coming back. Participants are split into two groups: standard-risk patients get standard therapy, while high-risk patients receive an experimental drug combination (temsirolimus, temozolomide, and irinotecan) before standard treatment. The goal is to see if this approach shrinks tumors and improves long-term survival. All participants are followed for 10 years.